Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;36(4):743-750.
doi: 10.1007/s10103-020-03076-1. Epub 2020 Jun 27.

Efficient photodynamic therapy against drug-resistant prostate cancer using replication-deficient virus particles and talaporfin sodium

Sharmin Akter  1   2 , Sachiko Saito  3 , Mizuho Inai  4 , Norihiro Honda  3   5 , Hisanao Hazama  3 , Tomoyuki Nishikawa  6 , Yasufumi Kaneda  6 , Kunio Awazu  3   4   7
Affiliations

Efficient photodynamic therapy against drug-resistant prostate cancer using replication-deficient virus particles and talaporfin sodium

Sharmin Akter et al. Lasers Med Sci. 2021 Jun.

Erratum in

Abstract

To enhance the potency of photosensitizer, we developed a novel photosensitizer, Laserphyrin®-HVJ-E (L-HVJ-E), by incorporating talaporfin sodium (Laserphyrin®, Meiji Seika Pharma) into hemagglutinating virus of Japan envelope (HVJ-E). In this study, we examined the optimal Laserphyrin® concentration for preparation of Laserphyrin®-HVJ-E which had photocytotoxicity and maintained direct cytotoxicity derived from HVJ-E. Then, potency of Laserphyrin®-HVJ-E and Laserphyrin® were compared in vitro using castration-resistant prostate cancer cell line (PC-3). A laser diode (L660P120, Thorlabs, USA) with a wavelength of 664 nm was used for light activation of Laserphyrin®, which corresponds to an absorption peak of Laserphyrin® and provides a high therapeutic efficiency. The photocytotoxicity and direct cytotoxicity of Laserphyrin®-HVJ-E prepared using various Laserphyrin® concentrations were evaluated using PC-3 cell in vitro. We categorized the treatment groups as Group 1: 50 μL of D-MEM treatment group, Group 2: HVJ-E treatment group, Group 3: Laserphyrin®-HVJ-E treatment group, and Group 4: Laserphyrin® treatment group. Group 3 was subjected to different concentrations of Laserphyrin®-HVJ-E suspension, and all groups were subjected to different incubation periods (24, 48 h), (30 min, 1 h, or 3 h,) respectively, without and after PDT. Laserphyrin®-HVJ-E prepared using 15 mM Laserphyrin® had high photocytotoxicity and maintained HVJ-E's ability to induce direct cytotoxicity. Therapeutic effect of Laserphyrin®-HVJ-E was substantially equivalent to that of Laserphyrin® alone even at half Laserphyrin® concentration. By utilizing Laserphyrin®-HVJ-E, PDT could be performed with lower Laserphyrin® concentration. In addition, Laserphyrin®-HVJ-E showed higher potency than Laserphyrin® by combining cytotoxicities of HVJ-E and PDT.

Keywords: Hemagglutinating virus of Japan envelope; Photodynamic therapy; Prostate cancer; Talaporfin sodium.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Ferlay J et al (Mar. 2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386 - DOI
    1. Zhou CK et al (Mar. 2016) Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer 138(6):1388–1400 - DOI
    1. Survival rates for prostate cancer. [Online]. Available: https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-stagin... . [Accessed: 26-Dec-2019]
    1. Semenas J, Allegrucci C, Boorjian SA, Mongan NP, Liao Persson J (2012) Overcoming drug resistance and treating advanced prostate Cancer. Curr Drug Targets 13(10):1308–1323 - DOI
    1. Juarranz Á, Jaén P, Sanz-Rodríguez F, Cuevas J, González S (2008) Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol 10(3):148–154 - DOI

LinkOut - more resources